David Nierengarten
Stock Analyst at Wedbush
(3.68)
# 750
Out of 4,931 analysts
197
Total ratings
44.65%
Success rate
8.04%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $2.09 | -80.86% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $673.15 | +6.22% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.82 | +187.96% | 4 | Jun 23, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $11.97 | +83.79% | 2 | Jun 12, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 | $2.35 | +112.77% | 9 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.11 | +18.69% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $11.37 | -12.05% | 9 | May 19, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $11.39 | +137.05% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $32.72 | +3.91% | 3 | Apr 16, 2025 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $10.46 | +215.64% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.82 | +144.59% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.04 | +380.77% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $10.44 | +196.93% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $22.54 | +77.46% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $36.32 | +147.80% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $34.62 | +35.78% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $77.23 | +48.91% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $8.52 | +169.95% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $9.88 | +102.43% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $14.25 | +180.70% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $15.93 | +182.49% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.73 | +478.03% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.87 | +527.18% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $59.21 | -3.73% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $4.28 | +1,068.22% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $10.97 | -8.84% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $7.49 | +380.64% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.07 | +194.84% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $18.30 | +211.48% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $6.70 | +2,511.94% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $4.09 | +12,124.94% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.03 | +1,388.83% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.16 | +132.84% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $28.05 | +167.38% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.17 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.40 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.92 | - | 3 | Nov 20, 2017 |
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $2.09
Upside: -80.86%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $673.15
Upside: +6.22%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.82
Upside: +187.96%
Telix Pharmaceuticals
Jun 12, 2025
Reiterates: Outperform
Price Target: $22
Current: $11.97
Upside: +83.79%
Nuvation Bio
Jun 11, 2025
Maintains: Outperform
Price Target: $5
Current: $2.35
Upside: +112.77%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.11
Upside: +18.69%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $11.37
Upside: -12.05%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $11.39
Upside: +137.05%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $32.72
Upside: +3.91%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $10.46
Upside: +215.64%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.82
Upside: +144.59%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.04
Upside: +380.77%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $10.44
Upside: +196.93%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $22.54
Upside: +77.46%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $36.32
Upside: +147.80%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $34.62
Upside: +35.78%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $77.23
Upside: +48.91%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $8.52
Upside: +169.95%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.88
Upside: +102.43%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $14.25
Upside: +180.70%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $15.93
Upside: +182.49%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.73
Upside: +478.03%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.87
Upside: +527.18%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $59.21
Upside: -3.73%
Aug 8, 2024
Reiterates: Outperform
Price Target: $50
Current: $4.28
Upside: +1,068.22%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $10.97
Upside: -8.84%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $7.49
Upside: +380.64%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.07
Upside: +194.84%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $18.30
Upside: +211.48%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $6.70
Upside: +2,511.94%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $4.09
Upside: +12,124.94%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.03
Upside: +1,388.83%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.16
Upside: +132.84%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $28.05
Upside: +167.38%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.17
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.40
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $7.92
Upside: -